Synapse - Matthew Matasar

Results (23)

Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
Blood (2020)

Fulltext@MSK | Save

Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma

Meeting Abstract

Kumar, A.; Westin, J.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Batlevi, C. L.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
Blood (2020)

Fulltext@MSK | Save

CD5-positive marginal zone lymphoma: Clinical characteristics of the MSKCC Cohort, and comparison with the CD5-negative population

Meeting Abstract

Ghione, P.; Bantilan, K. S.; Joffe, E.; Lia Palomba, M.; Noy, A.; Matasar, M. J.; Caron, P.; Hamilton, A.; Hamlin, P. A.; Kumar, A.; more...
Blood (2020)

Fulltext@MSK | Save

Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies

Journal Article

Sermer, D.; Batlevi, C.; Lia Palomba, M.; Shah, G.; Lin, R. J.; Perales, M. A.; Scordo, M.; Dahi, P.; Pennisi, M.; Afuye, A.; more...
Blood Advances (2020)

Fulltext@MSK | Save

Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma

Journal Article

Sermer, D.; Bobillo, S.; Dogan, A.; Zhang, Y.; Seshan, V.; Lavery, J. A.; Batlevi, C.; Caron, P.; Hamilton, A.; Hamlin, P.; more...
Blood Advances (2020)

Fulltext@MSK | Save

Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Meeting Abstract

Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
Blood (2019)

Fulltext@MSK | Save

High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
Blood (2019)

Fulltext@MSK | Save

Expectant management of extranodal marginal zone lymphoma of bronchial-associated lymphoid tissue (BALT)

Meeting Abstract

Leyfman, Y.; Joffe, E.; Drill, E.; Rajeeve, S.; Zelenetz, A. D.; Palomba, M. L. L.; Moskowitz, C. H.; Portlock, C. S.; Noy, A.; Horwitz, S. M.; more...
Blood (2019)

Fulltext@MSK | Save

Central nervous system prophylaxis with high-dose intravenous methotrexate or intrathecal chemotherapy in patients with diffuse large B-cell lymphoma and high-risk of CNS relapse treated in the rituximab era